Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin

Published:2010-11-02 Issue:1 Volume:66 Page:180-183
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:Journal of Antimicrobial Chemotherapy

Author:

Lamorde M.,Byakika-Kibwika P.,Okaba-Kayom V.,Ryan M.,Coakley P.,Boffito M.,Namakula R.,Kalemeera F.,Colebunders R.,Back D.,Khoo S.,Merry C.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/66/1/180/2155703/dkq411.pdf

Reference8 articles.

1. Incidence and risk factors for nevirapine-associated rash

2. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals

3. Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics;Expert Review of Clinical Pharmacology;2024-02-14

2. Methadone Reduced Nevirapine Pharmacokinetic Parameters in People Living With HIV in Malaysia;Malaysian Journal of Medicine and Health Sciences;2023-05-15

3. Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda;African Journal of Laboratory Medicine;2023-02-07

4. Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations;Journal of Personalized Medicine;2022-12-05

5. Evaluation of Namibia’s antiretroviral therapy guidelines’ recommendations for switching from first-line to second-line, using predictors of first-line treatment failure: an exploratory study;Expert Review of Anti-infective Therapy;2022-01-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3